Background: The presence of epidermal growth factor receptor (EGFR) mutations is associated with sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but a subset of patients (pts) do not respond to EGFR-TKIs or have very short duration of response, suggesting intrinsic resistance. Moreover, acquired resistance to EGFR-TKIs is inevitable for most patients. We showed that overexpression of Cripto-1, a member of the EGFeCFC family, contributes to the development of intrinsic resistance to EGFR-TKIs through the activation of the Src pathway and that the combination of EGFR-TKI therapy and Src inhibition works synergistically in preclinical models. Method: This was an open-label, phase I/II trial of osimertinib and dasatinib, a multi-kinase inhibitor with activity against Src, in EGFR-TKI treatment-naïve pts with advanced EGFR-mutant NSCLC (NCT02954523). Pts with pleural or pericardial effusions at study entry were excluded. The primary endpoint of the phase I part was to establish a safe and tolerable phase II dose of osimertinib and dasatinib. Dose escalation included 2 dose levels (dose level 1: osimertinib 80 mg QD, dasatinib 50 mg BID, dose level 2: osimertinib 80 mg QD, dasatinib 70 mg BID). In addition, 2 dose levels below the starting dose level could be explored if dose reductions were necessary. Result: 7 pts (4 at dose level 1, 3 at dose level 2) were enrolled to date. None of them had dose limiting toxicities (DLTs), but given frequent dose reductions and toxicities beyond the DLT period at dose level 2, dose level 1 is being further assessed (up to 6 pts at dose level 1). The most common treatment-related adverse events (TRAEs) included pleural effusion (n¼6), AST elevation (n¼5), ALT elevation (n¼5), rash (n¼5), and diarrhea (n¼4), most of which were grade 1 or 2. 3/2/1 pts had grade 1/2/3 pleural effusion, respectively. 4 pts had grade 3 TRAEs, which included pleural effusion, fatigue, neutropenia, anemia, and headaches. No grade 4 or 5 toxicities were observed. Among 6 evaluable pts, 4 confirmed partial response (PR)/1 unconfirmed PR/1 stable disease were observed. Responses were durable with all the PRs ongoing. Conclusion: The combination of dasatinib and osimertinib showed no new safety signals and demonstrated evidence of anticancer activity. Treatment-related toxicities were manageable with dasatinib dose reductions and supportive measures. The safety and efficacy of dasatinib and osimertinib will continue to be explored.
Background: Nab-Paclitaxel (PTX) plus gemcitabine significantly improved overall survival, progression-free survival, and response rate in patients with metastatic pancreatic adenocarcinoma. Anti-tumor synergy between nab-PTX and gemcitabine was recently demonstrated in mouse model. Combination treatment increases intra-tumoral gemcitabine levels attributable to a decrease in the primary gemcitabine metabolizing enzyme, cytidine deaminase. Higher caveolin-1 expression in tumor-associated stroma was associated with improved overall survival and response rate in patients with advanced non-small-cell lung cancer (NSCLC) treated with nab-PTX. Based on these data, we planned to assess the efficacy and safety of combination with nab-PTX plus gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy. Method: Patients with advanced NSCLC with progressive disease to platinum-based chemotherapy, ECOG performance status (PS) 0 or 1, and adequate kidney, liver and bone marrow function were eligible. Treatment consisted of nab-PTX (100 mg/m 2 ) plus gemcitabine (1000 mg/m 2 ) on days 1 and 8 of each 3week cycle until progression disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Archived tumor blocks, if available, were collected for caveolin-1 expression analysis using immunohistochemistry. Result: Of the 28 patients enrolled, 28 were evaluable for response and toxicity. The median age was 68 years (range 47-79), 23 males and 5 females. Histology subtypes were: adenocarcinoma 19 patients, squamous cell carcinoma 9 patients. Seventeen patients had ECOG PS 1 and 11 patients had PS 0. Twentyfour patients were 2nd line and 4 patients were 3rd line. The median number of cycles administered was 4 (range 1-10). The overall response rate was 17.9%. The disease control rate was 67.9%. The median progression-free survival was 3.1 months (95% confidence interval [CI] ¼ 1.6-4.1). The median overall survival was 11.7 months (95% CI ¼ 8.0-19.3). Five patients (17.9%) had grade 4 neutropenia, 4 patients (14.3%) had grade 3 anemia, 3 patients (10.7%) had grade 3 thrombocytopenia. However, no patients developed febrile neutropenia. Remarkable non-hematologic toxicity was interstitial pneumonia with grade 3 in 4 patients (14.3%), neuropathy with grade 3 in 2 patients (7.1%) and infections with grade 3 in 2 patients (7.1%). Caveolin-1 expression analysis will be presented at the meeting. Conclusion: The efficacy of nab-Paclitaxel in combination with gemcitabine in advanced second or third-line NSCLC patients was limited and the high onset of interstitial pneumonia was unacceptable. Keywords: nab-paclitaxel plus gemcitabine, caveolin-1 expression, Nonsmall-cell lung cancer P1.01-49 irAE, Possible Predictive Markers for Immune Checkpoint Inhibitors K. Komiya, 1 T. Nakamura, 1 H. Hirakawa, 1 S. Ogusu, 1 C. Nakashima, 2 K. Takahashi, 2 S. Kimura, 2 N. Sueoka-Aragane 2 1 Saga University, Saga/JP, 2 Internal Medicine, Saga University, Saga/JP Background: Although an immune-related adverse event (irAE) in immune checkpoint inhibitors (ICIs) is a major cause of discontinuation of ICIs, few reports have examined detailed clinical background in clinical practice. Method: Sixty-one patients with non-small cell lung cancer who underwent treatment with ICIs (nivolumab or pembrolizumab) at the Saga University Medical School Hospital from December 2015 to January 2018 were included. Clinical background, therapeutic effect, and progression free survival (PFS) were retrospectively examined between AE discontinuation group (AEg) and progressive disease (PD) discontinuation group (PDg). Result: Of the 41 patients receiving nivolumab, nine cases (22.5%) were discontinued due to AE and 22 cases (55.0%) were PD. Of 21 patients receiving pembrolizumab, nine cases (42.9%) were discontinued due to AE and 8 cases (38.1%) were PD. There was no significant difference between nivolumab and pembrolizumab in the discontinuation rate due to AE (p¼0.14) . When comparing the clinical background between the AEg and the PDg, the response rate was 50.0% in the AEg and 6.7% in the PDg, which was significantly higher in the AEg (p¼0.001). The median PFS was significantly longer in the AEg, 301 days (95% CI: 193-336) in the AEg and 60 days (95% CI: 74-178) in the PDg (Log-Rank, p¼0.009). Among irAE, the incidence of interstitial lung disease (ILD) was 3/49 (6.1%) in cases without interstitial pneumonia (IP) or radiation pneumonitis as the underlying diseases, whereas it was significantly higher at 6/12 (50.0%) in cases with those underlying diseases (p¼0.001). Among nine patients who developed ILD, grade3 or more was 2 cases, of which 1 case was grade5. Conclusion: Discontinuation due to AE during treatment of ICIs may be a predictive marker of good response to ICIs and favorable outcome since anti-cancer effect continued even after discontinuation. However, the presence of IP or radiation pneumonitis as the underlying disease is a risk factor for the onset of ILD, so it is necessary to carefully consider the indication for treatment of ICIs. Keywords: immune checkpoint inhibitor, predictive marker, immune-related adverse event (irAE) P1.01-50 Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC) D. Ksienski, 1 E. Wai, 2 M. Lesperance, 3 N. Croteau, 3 L. Fiorino, 1 Z. Poonja, 1 G. Geller, 1 D. Fenton, 1 E. Brooks, 1 D. Glick 2 1 Medical Oncology, BC Cancer Victoria, Victoria, BC/CA, 2 Radiation Oncology, BC Cancer-Victoria, Victoria, BC/CA, 3 University of Victoria, Victoria, BC/CA Background: Immune related adverse events (irAE) from immunotherapy in metastatic melanoma have been correlated with efficacy; this association is less clear in mNSCLC. We aimed to evaluate the correlation between irAE and clinical efficacy of Nivolumab (N) in mNSCLC. Method: All mNSCLC patients (pts) treated with N between 11/2015 to 10/2017 at BC Cancer were identified. Demographic, tumor, treatment details, and frequency and grade (Gr, CTCAE v4.0) of irAE, were collected from chart review. Kaplan-Meier curves of overall survival (OS) from initiation of N based on the development of irAE and utilizing a 6-week landmark analysis were evaluated using the log-rank test. Result: Characteristics of cohort (n¼230): median age 64y (range 39-82), primary histology: non-squamous (74%), brain metastases rate: 13%, ECOG PS>1: 31% at start of N, and median Charlson Comorbidity Index (CCI) 6, and 72% of pts had received 1 prior line of systemic therapy. 100 pts (44%) experienced 143 separate irAE of Gr 1(64), Gr 2(54), Gr 3(12), Gr 4(9), and Gr 5(4). Three treatment related deaths were due to pneumonitis, hepatitis and colitis. 48 pts (21%) required treatment interruption due to irAE, of whom 28 discontinued N completely. With a median follow-up of 7.0 months (range: 0.07-30), 136 pts died and median OS from initiation of N was 9.2 months (95% CI 7.8-12.9). Median OS was 12.9 months and 8.6 months for patients requiring treatment interruption due to irAE or not, respectively. For landmark analysis, 15 pts were excluded as they died within 6 weeks from initiation of N. Using 6-week landmark analysis, there was no significant difference in OS amongst pts who developed any irAE (median 8.1 months, 95% CI: 6.1-not reached) compared to those who did not (median 10.8 months, 95% CI: 8.6-14.5; log rank test p¼0.567). Development of colitis was associated with a lower median OS (4.4 months, 95% CI: 3.8-not reached) versus pts who did not (10.8 months, 95% CI: 8.6-14.5; p¼0.0103). Thyroid changes (p¼0.473), dermatitis (p¼0.29), pneumonitis (p¼0.318), hepatitis (p¼0.135), and arthralgias (p¼0.465) were not associated with different OS compared to those without irAE. Conclusion: Despite 31% of pts having PS>1 and a high CCI, N was well tolerated. In the studied cohort, development of any irAE was not associated with improved survival. The finding of worse survival amongst pts with colitis requires further study. Keywords: immune related adverse events, Nivolumab P1.01-51 Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC) D. Ksienski, 1 E. Wai, 2 M. Lesperance, 3 N. Croteau, 3 L. Fiorino, 1 Z. Poonja, 1 D. Fenton, 1 G. Geller, 1 E. Brooks, 1 D. Glick 2 1 Medical Oncology, BC Cancer Victoria, Victoria, BC/CA, 2 Radiation Oncology, BC Cancer-Victoria, Victoria, BC/CA, 3 University of Victoria, Victoria, BC/CA Background: Immune related adverse events (irAE) from immunotherapy in metastatic melanoma correlate with efficacy; this association is less clear in mNSCLC. We aimed to evaluate the correlation between irAE and clinical efficacy of pembrolizumab (P) in mNSCLC. Method: All mNSCLC patients (pts) treated with P between 11/2015 to 10/2017 at BC Cancer were identified. Demographic, tumor, treatment details, and frequency and grade (Gr, CTCAE v4.0) of irAE, were collected from chart review. Kaplan-Meier curves of overall survival (OS) from initiation of P based on the development of irAE and utilizing a 6-week landmark analysis were evaluated with the log-rank test. Result: Characteristics of cohort of 41 pts were: median age 68y (range 50-81), females 49%, non-squamous histology 81%, PD-L1 status <1%/1-49%/>50%/unknown 0/12%/83%/5%, brain metastases rate 15%, and liver metastases rate 12%. ECOG PS>1 at start of IO 32% and median Charlson Comorbidity Index (CCI) 4. P was delivered to 42% in first line setting. With a median of follow-up of 6.6 months (range: 0.7-32.3), 17 pts (41%) had died and 16 (39%) were still receiving drug. 16 pts (39%) experienced a total of 24 irAE; Gr of irAE 1/2/3/4/5: 10/12/ 1/1/0. The most common irAE were arthralgias (5pts), pneumonitis (4pts), and dermatitis (4pts). Treatment was temporarily held in 4pts (10%) due to irAE and permanently discontinued in 3 pts (7%). Median OS from initiation of P was 22.6 months (range: 10.6-not reached, NR). On univariate analysis, male gender (HR¼3.36, 95% CI: 1.08-10.48) and ECOG>1 (HR¼3.24, 95% CI: 1.13-9.35) correlated with worse OS. Median OS amongst pts requiring treatment interruption due to irAE was NR and for those treated continuously was 14.0 months. 1 pt was excluded from landmark analysis as they died within 6 week from initiation of P. Using 6 week landmark analysis, there was no significant difference in OS amongst pts who developed any irAE (median NR, 95% CI: 4.8 months-NR) compared to those who did not (14.0 months, 95% CI: 10.6-NR, log rank test p¼0.84). Thyroid changes (p¼0.411) and dermatitis (p¼0.951) were not associated with differences in OS compared to those without irAE. Conclusion: Despite 32% of pts having PS>1 and a high CCI, the incidence of serious irAE was low. The impact of gender on response to P requires more study. Development of irAEs was not correlated with improved survival. Keywords: pembrolizumab, immune related adverse events
